peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

ActRII antibody

Bimagrumab

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

This statement describes bimagrumab’s target and intended pathway effect; it does not provide dosing, clinical outcomes, or quantified effects. This identifies ACVR2B as the primary target but does not quantify affinity or functional consequences in this sentence. This states the planned endpoints; it does not alone indicate the magnitude of effect.

Sources for this introduction: [1] [2] [3]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

This statement describes bimagrumab’s target and intended pathway effect; it does not provide dosing, clinical outcomes, or quantified effects.

Sources[4]pubmedPutting the brakes on muscle growth: Myostatin as regulator of disuse atrophy.bimagrumab, a monoclonal antibody against ActRIIB and inhibitor of downstream myostatin signalling.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “bimagrumab, a monoclonal antibody against ActRIIB and inhibitor of downstream myostatin signalling.”

    Putting the brakes on muscle growth: Myostatin as regulator of disuse atrophy. · Abstract

    pubmed:42503042:0a3f96c9af02:0a3f96c9af02

How does it work?

Target, response, and disposition.

Mechanism

This identifies ACVR2B as the primary target but does not quantify affinity or functional consequences in this sentence.

Sources[1]iuphar-commentsIUPHAR ligand commentaryBimagrumab primarily targets the type II activin receptor ACVR2B [Reference 26666],
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Bimagrumab primarily targets the type II activin receptor ACVR2B [Reference 26666],”

    IUPHAR ligand commentary · Mechanism of action

    iuphar-comments:8086:ea8a7a8a6b51:ea8a7a8a6b51

Mechanism

Bimagrumab interferes with ligand–receptor interaction by inhibiting myostatin binding to the activin type IIB receptor (ACVR2B).

Sources[1]iuphar-commentsIUPHAR ligand commentaryBimagrumab inhibits myostatin binding to ACVR2B[1]iuphar-commentsIUPHAR ligand commentaryBimagrumab inhibits myostatin binding to ACVR2B,
Source records
2
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Bimagrumab inhibits myostatin binding to ACVR2B”

    IUPHAR ligand commentary · Bioactivity

    iuphar-comments:8086:ea8a7a8a6b51:ea8a7a8a6b51
  2. supports · Source-backed record
    “Bimagrumab inhibits myostatin binding to ACVR2B,”

    IUPHAR ligand commentary · Bioactivity

    iuphar-comments:8086:ea8a7a8a6b51:ea8a7a8a6b51

What has been studied?

What the evidence says.

Comparative evidence

This was a randomized, double-blind, placebo-controlled study lasting 6 months, with up to 6 more months of follow-up.

Sources[3]pubmedCardiac safety of chronic inhibition of the myostatin-activin pathway with bimagrumab in healthy older adults.Randomized, double-blind, placebo-controlled study with 6 months of treatment and up to 6 months of follow-up.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Randomized, double-blind, placebo-controlled study with 6 months of treatment and up to 6 months of follow-up.”

    Cardiac safety of chronic inhibition of the myostatin-activin pathway with bimagrumab in healthy older adults. · DESIGN

    pubmed:41873146:8a91427e0a64:8a91427e0a64

Study findings

This states the planned endpoints; it does not alone indicate the magnitude of effect.

Sources[2]pubmedBimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.The primary and secondary endpoints were absolute change from baseline in body weight at week 48 and week 72, respectively.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The primary and secondary endpoints were absolute change from baseline in body weight at week 48 and week 72, respectively.”

    Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. · Abstract

    pubmed:41772149:24cb24940d24:24cb24940d24

Study findings

In a Smad-dependent reporter gene assay, bimagrumab blocks downstream signalling triggered by myostatin.

Sources[1]iuphar-commentsIUPHAR ligand commentarythereby blocking myostatin-induced signalling as measured by a Smad dependent reporter gene assay
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “thereby blocking myostatin-induced signalling as measured by a Smad dependent reporter gene assay”

    IUPHAR ligand commentary · Bioactivity

    iuphar-comments:8086:ea8a7a8a6b51:ea8a7a8a6b51

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, interaction, regulatory, safety
  • 142 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (79), assurance_score_below_0.72 (54), current_regulatory_source_required (23), extraction_ambiguity (79), high_risk_requires_regulatory_or_two_independent_sources (58), no_direct_support (132), proposal_not_staged (3)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. IUPHAR ligand commentary ↗

    iuphar-comments · published 2026-08-25 · retrieved 2026-08-25T22:58:23Z

  2. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. ↗

    pubmed · published 2026-03-01 · retrieved 2026-08-25T22:58:23Z

  3. Cardiac safety of chronic inhibition of the myostatin-activin pathway with bimagrumab in healthy older adults. ↗

    pubmed · published 2026-08-13 · retrieved 2026-08-25T22:58:23Z

  4. Putting the brakes on muscle growth: Myostatin as regulator of disuse atrophy. ↗

    pubmed · published 2026-07-26 · retrieved 2026-08-25T22:58:23Z

Publication history and provenance

Version 6 · Automated assessment · 2026-08-28T12:09:49Z

5aaee3ea851d7717847cbeb08548f166f5f57117abaa2b4b8251625959a83141